These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32110781)

  • 1. Immune-awakening revealed by peripheral T cell dynamics after one cycle of immunotherapy.
    Valpione S; Galvani E; Tweedy J; Mundra PA; Banyard A; Middlehurst P; Barry J; Mills S; Salih Z; Weightman J; Gupta A; Gremel G; Baenke F; Dhomen N; Lorigan PC; Marais R
    Nat Cancer; 2020 Feb; 1(2):210-221. PubMed ID: 32110781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell immune awakening in response to immunotherapy is age-dependent.
    Salih Z; Banyard A; Tweedy J; Galvani E; Middlehurst P; Mills S; Weightman J; Gupta A; Lorigan PC; Zhou C; Dhomen N; Valpione S; Marais R
    Eur J Cancer; 2022 Feb; 162():11-21. PubMed ID: 34952479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamics and survival associations of T cell receptor clusters in patients with pleural mesothelioma treated with immunotherapy.
    Desai AP; Kosari F; Disselhorst M; Yin J; Agahi A; Peikert T; Udell J; Johnson SH; Smadbeck J; Murphy S; Karagouga G; McCune A; Schaefer-Klein J; Borad MJ; Cheville J; Vasmatzis G; Baas P; Mansfield A
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37279993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression.
    Andersen R; Borch TH; Draghi A; Gokuldass A; Rana MAH; Pedersen M; Nielsen M; Kongsted P; Kjeldsen JW; Westergaard MCW; Radic HD; Chamberlain CA; Hölmich LR; Hendel HW; Larsen MS; Met Ö; Svane IM; Donia M
    Ann Oncol; 2018 Jul; 29(7):1575-1581. PubMed ID: 29688262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
    Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
    J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimelanoma activity of CTL generated from peripheral blood mononuclear cells after stimulation with autologous dendritic cells pulsed with melanoma gp100 peptide G209-2M is correlated to TCR avidity.
    Yang S; Linette GP; Longerich S; Haluska FG
    J Immunol; 2002 Jul; 169(1):531-9. PubMed ID: 12077285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma.
    Hogan SA; Courtier A; Cheng PF; Jaberg-Bentele NF; Goldinger SM; Manuel M; Perez S; Plantier N; Mouret JF; Nguyen-Kim TDL; Raaijmakers MIG; Kvistborg P; Pasqual N; Haanen JBAG; Dummer R; Levesque MP
    Cancer Immunol Res; 2019 Jan; 7(1):77-85. PubMed ID: 30425105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral CD8
    Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
    Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insight into immune profile associated with vitiligo onset and anti-tumoral response in melanoma patients receiving anti-PD-1 immunotherapy.
    Carbone ML; Capone A; Guercio M; Reddel S; Silvestris DA; Lulli D; Ramondino C; Peluso D; Quintarelli C; Volpe E; Failla CM
    Front Immunol; 2023; 14():1197630. PubMed ID: 37680638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.
    Yan Y; Wang X; Liu C; Jia J
    BMC Pulm Med; 2022 Apr; 22(1):166. PubMed ID: 35484541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
    Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
    BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion.
    Goff SL; Johnson LA; Black MA; Xu H; Zheng Z; Cohen CJ; Morgan RA; Rosenberg SA; Feldman SA
    Cancer Immunol Immunother; 2010 Oct; 59(10):1551-60. PubMed ID: 20628878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma.
    Hopkins AC; Yarchoan M; Durham JN; Yusko EC; Rytlewski JA; Robins HS; Laheru DA; Le DT; Lutz ER; Jaffee EM
    JCI Insight; 2018 Jul; 3(13):. PubMed ID: 29997287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy.
    Tvingsholm SA; Frej MS; Rafa VM; Hansen UK; Ormhøj M; Tyron A; Jensen AWP; Kadivar M; Bentzen AK; Munk KK; Aasbjerg GN; Ternander JSH; Heeke C; Tamhane T; Schmess C; Funt SA; Kjeldsen JW; Kverneland AH; Met Ö; Draghi A; Jakobsen SN; Donia M; Marie Svane I; Hadrup SR
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour infiltrating B cells discriminate checkpoint blockade-induced responses.
    Valpione S; Campana LG; Weightman J; Salih Z; Galvani E; Mundra PA; De Rosa F; Gupta A; Serra-Bellver P; Lorigan P; Germetaki T; Dynowski M; Kitcatt S; Sahoo S; Lee D; Dhomen N; Lord G; Marais R
    Eur J Cancer; 2022 Dec; 177():164-174. PubMed ID: 36347135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral T cell receptor repertoire features predict durable responses to anti-PD-1 inhibitor monotherapy in advanced renal cell carcinoma.
    Kato T; Kiyotani K; Tomiyama E; Koh Y; Matsushita M; Hayashi Y; Nakano K; Ishizuya Y; Wang C; Hatano K; Kawashima A; Ujike T; Fujita K; Nonomura N; Uemura M
    Oncoimmunology; 2021 Jan; 10(1):1862948. PubMed ID: 33537170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
    Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
    J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-spatial analysis of T cell receptor repertoire in esophageal squamous cell carcinoma patients treated with combined radiotherapy and PD-1 blockade.
    Yan C; Ma X; Guo Z; Wei X; Han D; Zhang T; Chen X; Cao F; Dong J; Zhao G; Gao X; Wang T; Jiang Y; Wang P; Pang Q; Zhang W
    Oncoimmunology; 2022; 11(1):2025668. PubMed ID: 35036077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of HTLV-1 proviral DNA in cell-free DNA: Potential for non-invasive monitoring of Adult T cell leukaemia/lymphoma using liquid biopsy?
    Joris T; Haddow J; Taylor GP; Cook LBM; Rowan AG
    Front Immunol; 2023; 14():1150285. PubMed ID: 37114063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
    Matsuzaki J; Lele S; Odunsi K; Tsuji T
    Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.